Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KAPA

Kairos Pharma Ltd.

Sep 27 • 04:00PM ET

1.54

Dollar change -0.12
Percentage change -6.95	%

Healthcare • Biotechnology • USA • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.16	Insider Own	-	Shs Outstand	12.84M	Perf Week	-29.68%
Market Cap	19.77M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	6.14M	Perf Month	-
Income	-2.01M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-0.21	P/B	-	EPS next Y	-	ROA	-199.80%	Short Interest	-	Perf Year	-
Cash/sh	0.00	P/C	988.68	EPS next 5Y	-	ROE	-	52W Range	1.51 - 4.00	Perf YTD	-40.77%
Dividend Est.	-	P/FCF	659.12	EPS past 5Y	-	ROI	-	52W High	-61.50%	Beta	-
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1.99%	ATR (14)	0.53
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-147.15%	Oper. Margin	0.00%	RSI (14)	-	Volatility	17.67% -
Employees	3	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-7.07%	Payout	-	Rel Volume	0.19	Prev Close	1.65
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	483.39K	Price	1.54
SMA20	-28.39%	SMA50	-28.39%	SMA200	-28.39%	Trades		Volume	91,112	Change	-6.95%

Sep-24-24 04:20PM	Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients (GlobeNewswire) -7.46%
Sep-17-24 04:29PM	Kairos Pharma Closing of $6.2 Million Initial Public Offering (GlobeNewswire) -5.38% -6.50%
Sep-16-24 10:49AM	Kairos Pharma Prices $6.2 Million Initial Public Offering (GlobeNewswire)

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KAPA

Kairos Pharma Ltd.

Upgrade your FINVIZ experience